Moreover, PPARγ agonists have also been associated with an increased incidence of subcutaneous sarcomas and elevated risk of bladder cancer, and tumor promotion may rely on PPARγ activation (Azoulay et al., 2012; Pruimboom-Brees et al., 2012). Here, PPARG is linked to neoplasm.